Skip Navigation


European Heart Journal Advance Access originally published online on May 3, 2007
European Heart Journal 2007 28(14):1783; doi:10.1093/eurheartj/ehm140
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/14/1783    most recent
ehm140v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Christersson, C.
Right arrow Articles by Wallentin, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Christersson, C.
Right arrow Articles by Wallentin, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM: reply

Christina Christersson

Department of Medical Sciences Cardiology and Clinical Chemistry Uppsala University Hospital
S-751 85 Uppsala
Sweden

Jonas Oldgren

Department of Medical Sciences Cardiology Uppsala University Hospital
Uppsala
Sweden

Anders Bylock

AstraZeneca R&D
Mölndal
Sweden

Agneta Siegbahn

Department of Medical Sciences Clinical Chemistry Uppsala University Hospital
Uppsala
Sweden

Lars Wallentin

Uppsala Clinical Research Center
Uppsala
Sweden

Tel: +46 18 611 90 68 Fax: +46 18 50 66 38 E-mail address: christina.christersson@akademiska.se

The first 10% of the full text of this article appears below.

The ESTEEM trial was a phase II study evaluating the efficacy and safety of treatment with the first available oral direct thrombin inhibitor ximelagatran together with aspirin, when compared with aspirin only, after a recent myocardial infarction.1 In a subgroup of 518 (out of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?